

CLAIM AMENDMENTS

Claims 1 through 19 (canceled).

1 Claim 20 (currently amended) Recombinant poxvirus
2 comprising in the viral genome at least two expression cassettes,
3 each comprising ~~[[the]]~~ a cowpox ATI promoter according to SEQ ID
4 NO:1, a polynucleotide sequence in which not more than 6
5 nucleotides are substituted, deleted, and/or inserted into SEQ ID
6 No:1 and still active as an ATI promoter, or a polynucleotide
7 comprising at least 10 nucleotides including nucleotides 22 to 29
8 of SEQ ID No: 1 and still active as an ATI promoter ~~or a derivative~~
9 ~~thereof or a subsequence of the ATI promoter or the derivative~~
10 thereof and a coding sequence, wherein the expression of the coding
11 sequence is regulated by said promoter or said polynucleotides ~~7~~
12 ~~derivative or subsequence and wherein the derivative of the cowpox~~
13 ~~ATI promoter is a sequence that has a homology of at least 60% when~~
14 ~~compared to the sequence of SEQ ID.: No. 1 and/or a sequence in~~
15 ~~which not more than 6 nucleotides are substituted, deleted and/or~~
16 ~~inserted in the sequence of SEQ ID.: No. 1, wherein the subsequence~~
17 ~~of the ATI promoter has a length of at least 10 nucleotides of the~~
18 ~~sequence of SEQ ID.: No. 1 and wherein the promoter, derivative or~~
19 ~~subsequence has the biological activity of being active as a~~
20 promoter.

1 Claim 21 (currently amended) Recombinant poxvirus
2 according to claim 20, wherein the Cowpox ATI promoter ~~, derivative~~
3 ~~or subsequence~~ has the biological activity of being active as a
4 Vaccinia virus late promoter.

1 Claim 22 (currently amended) Recombinant poxvirus
2 according to claim 20, wherein the Cowpox ATI promoter is SEQ ID
3 No: 1 or a promoter, derivative or subsequence polynucleotide which
4 comprises at least 10 nucleotides including nucleotides 25 to 29 or
5 22 to 29 of SEQ ID No:1 and still active as an ATI promoter.

1 Claim 23 (currently amended) Recombinant poxvirus
2 according to claim 20, wherein the Cowpox ATI promoters in each
3 expression cassette, derivatives or subsequences in the recombinant
4 poxvirus are the same identical to one another.

1 Claim 24 (previously presented) Recombinant poxvirus
2 according to claim 20, wherein at least two expression cassettes
3 are inserted into the same insertion site in the poxvirus genome.

1 Claim 25 (currently amended) Recombinant poxvirus
2 according to claim 20, wherein the Cowpox ATI promoter in at least
3 one of the expression cassettes has the sequence of SEQ ID.: No. 1.

1 Claim 26 (currently amended) Recombinant poxvirus
2 according to claim 20, wherein the Cowpox ATI promoter in ~~at least~~

3 ~~one of the expression cassettes is a derivative of the ATI promoter~~
4 ~~or a subsequence of the ATI promoter or a derivative thereof~~ has
5 the sequence of SEQ ID.: No. 1.

1 Claim 27 (previously presented) Recombinant poxvirus
2 according to claim 20, wherein the poxvirus is selected from the
3 group consisting of orthopoxviruses and avipoxviruses.

1 Claim 28 (previously presented) Recombinant poxvirus
2 according to claim 27, wherein the orthopoxvirus is a vaccinia
3 virus and wherein the avipoxvirus is selected from the group
4 consisting of canarypoxvirus and fowlpoxvirus.

1 Claim 29 (previously presented) Recombinant poxvirus
2 according to claim 28, wherein the vaccinia virus is modified
3 vaccinia virus strain Ankara (MVA), in particular MVA-BN and MVA
4 575, deposited under numbers V00083008 and V00120707, respectively,
5 at the European Collection of Animal Cell Cultures (ECACC).

1 Claim 30 (previously presented) Recombinant poxvirus
2 according to claim 29, wherein at least one of the expression
3 cassettes is inserted in a naturally occurring deletion site of the
4 MVA genome with respect to the genome of the vaccinia virus strain
5 Copenhagen.

1 Claim 31 (previously presented) Recombinant poxvirus
2 according to claim 20, wherein at least one of the expression
3 cassettes is inserted in an intergenic region of the poxvirus
4 genome.

1 Claim 32 (previously presented) Recombinant poxvirus
2 according to claim 20, wherein at least one of the coding sequences
3 codes for at least one antigen, antigenic epitope, and/or a
4 therapeutic compound.

Claim 33 (canceled)

1 Claim 34 (previously presented) Vaccine or
2 pharmaceutical composition comprising a recombinant poxvirus
3 according to claim 20.

Claim 35 (canceled)

1 Claim 36 (withdrawn) Method for introducing coding
2 sequences into target cells comprising the infection of the target
3 cells with the virus according to claim 20.

1 Claim 37 (withdrawn) Method for producing a peptide,
2 protein and/or virus comprising:

3 a) infection of a host cell with the recombinant poxvirus
4 according to claim 20,

5 b) cultivation of the infected host cell under suitable
6 conditions, and

7 c) isolation and/or enrichment of the peptide and/or
8 protein and/or viruses produced by said host cell.

1 Claim 38 (withdrawn) Method for effecting an
2 immunological response in a living animal host including a human
3 comprising administering the virus according to claim 20 to the
4 animal or human to be treated.

1 Claim 39 (withdrawn) Method according to claim 38
2 comprising the administration of at least 10^2 TCID₅₀ (tissue culture
3 infectious dose) of the virus.

1 Claim 40 (withdrawn) A cell containing the virus
2 according to claim 20.

1 Claim 41 (previously presented) A method for the
2 production of a recombinant virus according to claim 20 comprising
3 the step of inserting at least two expression cassettes into the
4 genome of a poxvirus.

1 Claim 42 (withdrawn) Method for effecting an
2 immunological response in a living animal host, including a human,
3 comprising administering the composition or vaccine according to
4 claim 34 to the animal or human to be treated.